tirzepatide and ulcerative colitis GLP-1 Therapy May Offer Added Benefit in IBD Beyond Weight Loss Frontiers | Advancing therapeutic frontiers:

GLP-1 drugs have large human weight-loss trials

A case of vesiculopustular eruption occurred 6 weeks after liraglutide use, with non-grouped vesicles and red borders on the thorax, abdomen, face, neck, arms, and lower extremities

Several bacteria exploit these dynamics to manipulate host cell survival and immunity

Molecular Structure GLP-3 (Triple Incretin Agonist) Peptide Class: Triple incretin receptor agonist (GLP-1R/GIPR/GCGR) Peptide Length: 39 amino acids (fatty-acid-modified analog) Key Features: Multi-receptor agonism, albumin-binding extension for prolonged activity Form: Lyophilized powder, research-grade Cagrilintide (Long-Acting Amylin Analog) Peptide Class: Long-acting amylin-receptor agonist Peptide Length: 37 amino acids (acylated amylin analog) Key Features: Enhanced stability, prolonged receptor engagement, high amylin-receptor affinity Form: Lyophilized powder, research-grade Both peptides are supplied independently and used in combination for multi-axis metabolic research

By engineering the C-terminal portion of Exendin-4 to include amino acid sequences from glucagon in addition to a fatty acid side chain, Evers and colleagues developed a potent balanced co-agonist peptide 14